La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Sinopharm Group Gestion
Gestion contrôle des critères 4/4
Le PDG Sinopharm Group's est Yong Liu, nommé en Nov2017, a un mandat de 6.75 ans. La rémunération annuelle totale est CN¥ 6.50M, composée du salaire de 33.5% et des bonus 66.5%, y compris les actions et options de la société. détient directement 0.002% des actions de la société, d'une valeur de HK$ 1.16M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.6 ans et 5.7 ans.
Informations clés
Yong Liu
Directeur général
CN¥6.5m
Rémunération totale
| Pourcentage du salaire du PDG | 33.5% |
| Durée du mandat du directeur général | 6.8yrs |
| Propriété du PDG | 0.002% |
| Durée moyenne d'occupation des postes de direction | 4.6yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.7yrs |
Mises à jour récentes de la gestion
Recent updates
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23
The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?
Jan 19At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?
Jan 06What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?
Dec 25Read This Before Buying Sinopharm Group Co., Ltd. (HKG:1099) Shares
Dec 15Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | CN¥9b |
| Dec 31 2023 | CN¥7m | CN¥2m | CN¥9b |
| Sep 30 2023 | n/a | n/a | CN¥9b |
| Jun 30 2023 | n/a | n/a | CN¥9b |
| Mar 31 2023 | n/a | n/a | CN¥9b |
| Dec 31 2022 | CN¥6m | CN¥2m | CN¥9b |
| Sep 30 2022 | n/a | n/a | CN¥8b |
| Jun 30 2022 | n/a | n/a | CN¥8b |
| Mar 31 2022 | n/a | n/a | CN¥8b |
| Dec 31 2021 | CN¥7m | CN¥2m | CN¥8b |
| Sep 30 2021 | n/a | n/a | CN¥8b |
| Jun 30 2021 | n/a | n/a | CN¥8b |
| Mar 31 2021 | n/a | n/a | CN¥8b |
| Dec 31 2020 | CN¥7m | CN¥2m | CN¥7b |
| Sep 30 2020 | n/a | n/a | CN¥7b |
| Jun 30 2020 | n/a | n/a | CN¥6b |
| Mar 31 2020 | n/a | n/a | CN¥6b |
| Dec 31 2019 | CN¥7m | CN¥2m | CN¥6b |
| Sep 30 2019 | n/a | n/a | CN¥6b |
| Jun 30 2019 | n/a | n/a | CN¥6b |
| Mar 31 2019 | n/a | n/a | CN¥6b |
| Dec 31 2018 | CN¥8m | CN¥2m | CN¥6b |
| Sep 30 2018 | n/a | n/a | CN¥6b |
| Jun 30 2018 | n/a | n/a | CN¥6b |
| Mar 31 2018 | n/a | n/a | CN¥5b |
| Dec 31 2017 | CN¥6m | CN¥1m | CN¥6b |
Rémunération vs marché: La rémunération totale de Yong ($USD 911.26K ) est dans la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 913.61K ).
Rémunération et revenus: La rémunération de Yong a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Yong Liu (55 yo)
6.8yrs
Titularisation
CN¥6,504,000
Compensation
Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chairman of the Board | 5.7yrs | CN¥6.74m | 0.0032% CN¥ 1.9m | |
| President & Executive Director | 6.8yrs | CN¥6.50m | 0.0019% CN¥ 1.1m | |
| Chief Financial Officer | 3.4yrs | pas de données | pas de données | |
| Secretary to the Board | 5.7yrs | pas de données | pas de données |
4.6yrs
Durée moyenne de l'emploi
54.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de 1099 est considérée comme expérimentée (ancienneté moyenne 4.6 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chairman of the Board | 5.7yrs | CN¥6.74m | 0.0032% CN¥ 1.9m | |
| President & Executive Director | 6.7yrs | CN¥6.50m | 0.0019% CN¥ 1.1m | |
| Non-Executive Vice Chairman | 14.3yrs | pas de données | pas de données | |
| Non-Executive Director | 3.2yrs | pas de données | pas de données | |
| Chief Supervisor | 3.2yrs | pas de données | pas de données | |
| Non-Executive Director | 17yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 3.9yrs | CN¥350.00k | pas de données | |
| Independent Non-Executive Director | 3.9yrs | CN¥350.00k | pas de données | |
| Non-Executive Director | 6.9yrs | pas de données | pas de données | |
| Non-Executive Director | 5.7yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 5.7yrs | CN¥350.00k | pas de données | |
| Independent Non-Executive Director | 3.9yrs | CN¥350.00k | pas de données |
5.7yrs
Durée moyenne de l'emploi
57yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de 1099 sont considérés comme expérimentés (ancienneté moyenne 5.7 ans).